Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996-2006

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 7, 2011, Pages 729-738

  Artama, Miia ^a   Gissler, Mika ^a,b   Malm, Heli ^c,d   Ritvanen, Annukka ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Major congenital anomalies; Medicine use; Perinatal health; Pregnancy; Reimbursement

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CENTRAL STIMULANT AGENT; CORTICOSTEROID; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; PSYCHOSTIMULANT AGENT;

ADULT; ARTICLE; ASTHMA; CONGENITAL MALFORMATION; DIABETES MELLITUS; DRUG SAFETY; DRUG USE; EPILEPSY; FEMALE; FINLAND; HUMAN; HYPOTHYROIDISM; INDUCED ABORTION; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL; REGISTER; REIMBURSEMENT; RHEUMATOID ARTHRITIS;

ADULT; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; MEDICAL RECORD LINKAGE; MULTIVARIATE ANALYSIS; PHARMACOEPIDEMIOLOGY; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRESCRIPTION DRUGS; REGISTRIES; YOUNG ADULT;

EID: 79959727290     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2159     Document Type: Article

References (56)

1. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-1736.
2. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP Group. Eur J Clin Pharmacol 1999; 55: 139-144.
3. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation-a Finnish register-based study. Eur J Clin Pharmacol 2003; 59: 127-133.
4. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11: 854-858.
5. Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry. Epilepsia 2004; 45: 1465.
6. Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-198.
7. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an International Registry of Antiepileptic Drugs and Pregnancy. Epilepsia 2004; 45: 1463-1464.
8. Lisi A, Botto LD, Robert-Gnansia E, et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the International Clearinghouse of births defects surveillance and research. Reprod Toxicol 2010; 29(4): 433-442.
9. Garne E, Dolk H, Loane M, Boyd PA. EUROCAT website data on prenatal detection rates of congenital anomalies. J Med Screen 2010; 17: 97-98.
10. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006; 15: 546-554.
11. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-2683.
12. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51: 264-270.
13. Yang T, Walker MC, Krewski D, et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 2008; 17: 270-277.
14. Kulaga S, Zagarzadeh A, Bérard A. Prescription filled during pregnancy for drugs with the potential of fetal harm. BJOG 2009; 116: 1788-1795.
15. Shaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy-15years experience of ENTIS. Reprod Toxicol 2005; 20: 331-343.
16. Bakker MK, Jentkin J, Vroom F, Van Den Berg PB, De Walle HEK, de Jong-van den Berg L. Drug prescription pattern before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559-568.
17. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 863-870.
18. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009; 65: 839-846.
19. Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can. Pharmacoepidemiol Drug Saf 2010; 19: 256-265.
20. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555-564.
21. Charlton RA, Cunnington MC, de Vries CS, Weil J. Data resources for investigating drug exposure during pregnancy and associated outcomes. Drug Saf 2008; 31: 39-51.
22. Irgens M. The Medical Birth registry of Norway. Epidemiological research and surveillance throughout 30years. Acta Obstet Gynecol Scand 2000; 79: 435-439.
23. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008; 65: 653-660.
24. Olesen C, Thrane N, Henriksen TB, Ehrenstein V, Olsen J. Associations between socio-economic factors and the use of prescription medication during pregnancy. Eur J Clin Pharmacol 2006; 62: 547-553.
25. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17: 701-704.
26. Nørgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformation: a Danish population-based cohort study. J Antimicrob Chemother 2008; 62: 172-176.
27. Källén B. The use of national health registers for studying environmental causes of congenital defects. Rev Environ Health 2005; 20: 57-64.
28. Olsen J, Czeizel A, Sørensen HT, et al. How do we best detect toxic effects of drugs taken during pregnancy? Drug Saf 2002; 25: 21-32.
29. Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol 2008; 26: 36-41.
30. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
31. Gissler M, Teperi J, Hemminki E, Meriläinen J. Data quality after restructuring a nationwide medical birth registry. Scand J Soc Med 1995; 23: 75-80.
32. Teperi J. Multi-method approach to the assessment of data quality in the Finnish Medical Birth Registry. J Epidemiol Community Health 1993; 47: 242-247.
33. Gissler M, Teperi J, Forssas E, Hemminki E. Syntymärekisterin luotettavuustutkimus 1991. Stakes Aiheita 11/1993 (in Finnish).
34. Gissler M, Ulander V-M, Hemminki E, Rasimus A. Declining induced abortion rate in Finland: data-quality of the Abortion Register. Int J Epidemiol 1996; 25: 376-380.
35. EUROCAT 2005. EUROCAT Guide 1.3 and reference documents. Instructions for the Registration and Surveillance of Congenital Anomalies.
36. Leonici E, Botto LD, Cocchi G, et al. How valid are the rates of Down syndrome internationally? Findings from the International Clearinghouse for Birth Defects Surveillance and Research. Am J Med Genet A 2010; 152A: 1670-1680.
37. Pakkasjärvi N, Ritvanen A, Herva R, Peltonen L, Kestilä M, Ignatius J. Lethal congenital contractur syndrome (LCCS) and other lethal arthrogryposes in Finland-an epidemiological study. Am J Med Genet A 2006; 140A: 1834- 1839.
38. Mossialos E, Srivastava D. Pharmaceutical policies in Finland: Challenges and opportunities. Ministry of Health and Social Affairs (Finland) and European Observatory on Health Systems and Policies. World Health Organization: Copenhagen, 2008; 17-19.
39. Social Insurance Institution of Finland. Statistical Yearbook of the Social Insurance Institution. Vammalan Kirjapaino Oy: Sastamala, 2009; 183.
40. National Agency for Medicines and Social Insurance Institution. Finnish Statistics on Medicines 2007. Edita Oy: Helsinki, 2008.
41. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs 2004. World Health Organization: Oslo, 2003.
42. Swedish System of Approved Drugs (FASS). Classification of Medical Products for Use during Pregnancy and Lactation: The Swedish System. LINFO, Drug Information Ltd: Stockholm, 1993.
43. Pihkala J, Hakala T, Voutilainen P, Raivio K. Uudet suomalaiset sikiön kasvukäyrät. Duodecim 1989; 105: 1540-1546 (in Finnish).
44. Gissler M, Haukka J. Finnish health and social welfare registers in epidemiological research. Nor Epidemiol 2004; 14: 113-120.
45. Rothman KJ, Greenland S. Accuracy considerations in study design. In Modern epidemiology (2nd edn), Rothman KJ, Greenland S (eds.). Lippincott Williams & Wilkins: Philadelphia, 1998; pp. 135-145.
46. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
47. Schirm E, Meijer WM, Tobi H, de Jong-vanden Berg LTW. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol Reprod Biol 2004; 114: 182-188.
48. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Pharmacol 2004; 60: 659-666.
49. Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription of hazardous drugs during pregnancy. Drug Saf 2004; 27: 899-908.
50. Olesen C, Sørensen HT, de Jong-van den Berg L, Olsen J, Steffensen FH, the EUROMAP Group. Prescribing during pregnancy and lactation with reference to Swedish classification system. A population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686-692.
51. European Medicines Agency (EMA). Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. [28 September 2010]
52. Crijns HJMJ, Straus SM, Gispen-de Wied Ch, de Jong-van den Berg LTW. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 2011; 164: 238-244. DOI: 10.1111/j.1365- 2133.2010.09976.x
53. Gissler M, Artama M, Ritvanen A, Wahlbeck K. Use of psychotropic drugs before pregnancy and the risk for induced abortion: population-based register-data from Finland 1996-2006. BMC Public Health 2010; 10: 383.
54. Bonassi S, Magnani M, Calvi A, et al. Factors related to drug consumption during pregnancy. Acta Obstet Gynecol Scand 1994; 73: 535-540.
55. Rubin J, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs during pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol 1993; 46: 581-589.
56. Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J for the EuroMAP Group. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12: 497-501.